Similar to the use of METCAM/MUC18 for the clinical treatment of ovarian cancer, three general strategies may be useful for designing therapeutic means: (a) the reconstitution of the METCAM/MUC18 gene by gene therapy or activation of the tumor/metastasis suppressor genes by activation of the locus on chromosome 11q23.3, (b) directly administering the recombinant METCAM/MUC18 protein to the patients, and (c) aiming at key members in the downstream pathways that are activated by the loss of the metastasis suppressor function [31]. This evidence concerns the gene MCAM and ovarian carcinoma.